Faculty Opinions recommendation of Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.

2015 ◽  
Author(s):  
Sarah Donaldson
Keyword(s):  
North American ◽  
Pooled Analysis ◽  
Cooperative Groups ◽  
Pediatric Age

scholarly journals Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups

2014 ◽  
Vol 25 (1) ◽  
pp. 231-236 ◽  
Author(s):  
J.H.M. Merks ◽  
G.L. De Salvo ◽  
C. Bergeron ◽  
G. Bisogno ◽  
A. De Paoli ◽  
...  
Keyword(s):  
North American ◽  
Pooled Analysis ◽  
Cooperative Groups ◽  
Pediatric Age

Parameningeal rhabdomyosarcoma: Results of a pooled analysis from U.S. and European Cooperative Groups.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 9529-9529 ◽  
Author(s):  
J. H. Merks ◽  
G. L. De Salvo ◽  
C. Bergeron ◽  
G. Bisogno ◽  
A. Rey ◽  
...  
Keyword(s):  
Pooled Analysis ◽  
Cooperative Groups

scholarly journals Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups

2018 ◽  
Vol 36 (35) ◽  
pp. 3466-3476 ◽  
Author(s):  
David O. Walterhouse ◽  
Donald A. Barkauskas ◽  
David Hall ◽  
Andrea Ferrari ◽  
Gian Luca De Salvo ◽  
...  
Keyword(s):  
Tumor Size ◽  
Proportional Hazards ◽  
Selection Procedure ◽  
Pooled Analysis ◽  
Demographic Variables ◽  
Cooperative Groups ◽  
Treatment Variable ◽  
Treatment Choices ◽  
Prognostic Features ◽  
Kaplan Meier

Purpose Treatment recommendations for localized paratesticular rhabdomyosarcoma (PT RMS) differ in North America and Europe. We conducted a pooled analysis to identify demographic features and treatment choices that affect outcome. Patients and Methods We retrospectively analyzed the effect of nine demographic variables and four treatment choices on event-free survival (EFS) and overall survival (OS) from 12 studies conducted by five cooperative groups. Results Eight hundred forty-two patients with localized PT RMS who enrolled from 1988 to 2013 were included. Patients age ≥ 10 years were more likely than younger patients to have tumors that were > 5 cm, enlarged nodes (N1), or pathologically involved nodes ( P ≤ .05 each). With a median follow-up of 7.5 years, Kaplan-Meier estimates for 5-year EFS and OS were 87.7% and 94.8%, respectively. Of demographic variables, cooperative group, era of enrollment, age category, tumor size, Intergroup Rhabdomyosarcoma Study group, and T stage affected EFS ( P ≤ .05 each). Surgical assessment of regional nodes, which was performed in 23.5% of patients—usually in those age ≥ 10 years or with suspicious or N1 nodes—was the only treatment variable associated with EFS by univariable and multivariable analyses ( P ≤ .05 each) in patients age ≥ 1 year. A variable selection procedure on a proportional hazards regression model selected era of enrollment, age, tumor size, and surgical assessment of regional nodes as significant ( P ≤ .05 each) in the EFS model, and era of enrollment, age, tumor size, and histology ( P ≤ .05 each) in the OS model. Conclusion Localized PT RMS has a favorable prognosis. Age ≥ 10 years at diagnosis and tumor size larger than 5 cm are unfavorable prognostic features. Surgical assessment of regional nodes is important in patients age ≥ 10 years and in those with N1 nodes as it affects EFS.

scholarly journals Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

2015 ◽  
Vol 62 (12) ◽  
pp. 2125-2131 ◽  
Author(s):  
Odile Oberlin ◽  
Annie Rey ◽  
Kenneth L.B. Brown ◽  
Gianni Bisogno ◽  
Ewa Koscielniak ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Pooled Analysis ◽  
Cooperative Groups

scholarly journals Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials

2008 ◽  
Vol 26 (34) ◽  
pp. 5638-5644 ◽  
Author(s):  
Brian R. Leyland-Jones ◽  
Christine B. Ambrosone ◽  
John Bartlett ◽  
Matthew J.C. Ellis ◽  
Rebecca A. Enos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
North American ◽  
Ffpe Tissue ◽  
Cancer Clinical Trials ◽  
Cooperative Groups ◽  
Specimen Collection ◽  
Frozen Tissue ◽  
Fresh Frozen ◽  
Working Groups

Recommendations for specimen collection and handling have been developed for adoption across breast cancer clinical trials conducted by the Breast International Group (BIG)-sponsored Groups and the National Cancer Institute (NCI)-sponsored North American Cooperative Groups. These recommendations are meant to promote identifiable standards for specimen collection and handling within and across breast cancer trials, such that the variability in collection/handling practices that currently exists is minimized and specimen condition and quality are enhanced, thereby maximizing results from specimen-based diagnostic testing and research. Three working groups were formed from the Cooperative Group Banking Committee, BIG groups, and North American breast cancer cooperative groups to identify standards for collection and handling of (1) formalin-fixed, paraffin-embedded (FFPE) tissue; (2) blood and its components; and (3) fresh/frozen tissue from breast cancer trials. The working groups collected standard operating procedures from multiple group specimen banks, administered a survey on banking practices to those banks, and engaged in a series of discussions from 2005 to 2007. Their contributions were synthesized into this document, which focuses primarily on collection and handling of specimens to the point of shipment to the central bank, although also offers some guidance to central banks. Major recommendations include submission of an FFPE block, whole blood, and serial serum or plasma from breast cancer clinical trials, and use of one fixative and buffer type (10% neutral phosphate-buffered formalin, pH 7) for FFPE tissue across trials. Recommendations for proper handling and shipping were developed for blood, serum, plasma, FFPE, and fresh/frozen tissue.

Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 350-350 ◽  
Author(s):  
Ashwathy Susan Mathew ◽  
Eshetu G. Atenafu ◽  
Dawn Owen ◽  
Chris Maurino ◽  
Anthony M. Brade ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Local Control ◽  
North American ◽  
Stereotactic Body Radiation Therapy ◽  
Early Stage ◽  
Pooled Analysis ◽  
Stereotactic Body Radiation ◽  
Grade 3

350 Background: To report outcomes of pooled data from patients with early stage hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT) at two North American Institutions. Methods: An IRB approved collaborative review of patients with HCC treated with radical intent SBRT was conducted. Inclusion criteria included patients with Stage I-IIIA HCC (UICC/AJCC 7th Ed.) treated with SBRT (≥ 4.5 Gy/ fraction) from June 2003 until Dec 2016. Patients who were treated with SBRT were ineligible for resection, percutaneous ablative or hepatic intravascular therapies. Patients with vascular invasion and those treated with palliative intent (e.g. HCC rupture) were excluded. Overall survival, local control and toxicity of treatment were reviewed retrospectively. Results: Of 310 eligible patients, 23% were Child-Pugh (CP) class B/C (21%/2%), and 40% had failed prior liver directed therapies. The median HCC diameter was 2.4 cm (range 0.5-18.1 cm), and the median prescribed dose was 39 Gray (Gy) in 5 fractions (range: 14 - 60 Gy in 2-6 fractions). Median BED was 78.75 Gy (Range: 23.8-180.0 Gy). 8.4% of patients underwent liver transplant after SBRT. Local control at 1, 3 and 5 years was 91.5%, 82.6% and 82.6%. On multivariable analysis (MVA), the use of breath-hold motion management, but not T stage, size or dose, was significantly associated with local control (p = 0.0098). The 1, 3, and 5 year overall survival (OS) was 77.3%, 37.9% and 23.5%. Factors associated with improved OS on MVA included baseline CP A score (HR = 0.58, p < 0.0045), AFP < 10 µg/L (HR = 0.66, p = 0.0094), and transplant post SBRT (HR = 0.05, p < 0.0001). The median survival of CP A vs. B/C patients was 30.3 and 17.6 months respectively. CTCAE (v4.0) grade 3 or higher luminal gastrointestinal organ toxicity occurred in 2.5% of patients, while a decline in CP score ≥ 2 points was seen in 16.7% of patients at 3 months post SBRT. Grade 3 and above elevated liver enzymes were seen in 12.6% and 8.1% of patients at baseline and at 3 months post SBRT. Conclusions: Similar to Asian series, this North American pooled analysis found high sustained local control and excellent survival in patients with early stage HCC treated with SBRT.

scholarly journals Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies

2017 ◽  
Vol 8 (1) ◽  
pp. 17-32 ◽  
Author(s):  
David Pariser ◽  
Ellen Frankel ◽  
Joel Schlessinger ◽  
Yves Poulin ◽  
Ronald Vender ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
North American ◽  
Pooled Analysis ◽  
Phase 3 ◽  
Severe Plaque Psoriasis ◽  
The North

Localized vagina/uterus rhabdomyosarcoma (VU RMS): Results of a pooled analysis from four international cooperative groups.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 10063-10063
Author(s):  
Veronique Minard-Colin ◽  
James Robert Anderson ◽  
Gianni Bisogno ◽  
Dominique Schwob ◽  
David A. Rodeberg ◽  
...  
Keyword(s):  
Pooled Analysis ◽  
Cooperative Groups

scholarly journals Glomerular Filtration Rate in Former Extreme Low Birth Weight Infants over the Full Pediatric Age Range: A Pooled Analysis

2020 ◽  
Author(s):  
Elise Goetschalkx ◽  
Djalila Mekahli ◽  
Elena Levtchenko ◽  
Karel Allegaert
Keyword(s):  
Glomerular Filtration Rate ◽  
Birth Weight ◽  
Low Birth Weight ◽  
Cohort Studies ◽  
Filtration Rate ◽  
Pooled Analysis ◽  
Case Control ◽  
Pediatric Age ◽  
Single Center ◽  
Age Range

Different cohort studies documented a lower glomerular filtration rate (GFR) in former extremely low birth weight (ELBW, &lt;1000 g) neonates throughout childhood when compared to term controls. The current aim is to pool these studies to describe the GFR pattern over the pediatric age range. To do so, we conducted a systematic review on studies reporting on GFR measurements in former ELBW cases while GFR data of healthy age-matched controls included in these studies were co-collected. Based on 248 hits, 6 case-control and 3 cohort studies were identified, with 444 GFR measurements in 380 former ELBW cases (median age 5.3-20.7 years). The majority were small (17-78 cases) single center studies, with heterogeneity in GFR measurement (inulin, Cystatin C or creatinine estimated GFR formulae) tools. Despite this, the median GFR (ml/kg/1.73m2) within case-control studies was consistently lower (-13, range -8 to -25%) in cases, so that a relevant minority (15-30%) has a eGFR&lt;90 mgl/kg/1.73m2). Consequently, this pooled analysis describes a consistent pattern of reduced eGFR in former ELBW cases throughout childhood. Research should focus on perinatal risk factors for impaired GFR and long-term outcome, but is hampered by single center cohorts, study size, and heterogeneity of GFR assessment tools.

Sign in / Sign up

Export Citation Format

Share Document